Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)
Sponsor: Novocure
Participating sites:
- CHU UCL Namur, site Sainte Elisabeth, Namur
- UZ Gent, Gent
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- AZ Maria Middelares, Gent
- CHU Dinant Godinne, Yvoir
- Grand Hôpital de Charleroi, Charleroi
- Imelda ziekenhuis, Bonheiden
- CHU UCL St-Luc, Bruxelles